Aarkstore Enterprise Neuroblastoma – Pipeline Review, H1 2012

FOR IMMEDIATE RELEASE
Navi Mumbai, Maharashtra, India, Republic of (Free-Press-Release.com) February 27, 2012 -- http://www.aarkstore.com/categories/index.asp
Neuroblastoma – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, Neuroblastoma Pipeline Review, H1 2012, provides an overview of the Neuroblastoma therapeutic pipeline. This report provides information on the therapeutic development for Neuroblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroblastoma. Neuroblastoma Pipeline Review, H1 2012 is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

A snapshot of the global therapeutic scenario for Neuroblastoma.
A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.

A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Neuroblastoma pipeline on the basis of route of administration and molecule type.
Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Neuroblastoma.

Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Neuroblastoma therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information, please visit :-

http://www.aarkstore.com/reports/Neuroblastoma-Pipeline-Review-H1-2012-188495.html

Marketing Team

Aarkstore Enterprise

Phone:08149852585

Email:enquiry@aarkstore.com

URL:www.aarkstore.com

http://twitter.com/aarkstoredotcom

http://in.linkedin.com/in/aarkstore

http://www.facebook.com/aarkstoreenterprise

More Related Reports :-

Chemotherapy Effects – Pipeline Review, H1 2012
Follicular Lymphoma – Pipeline Review, H1 2012

Sleep Disorders – Pipeline Review, H1 2012
Neuroblastoma – Pipeline Review, H1 2012
Cytomegalovirus (HHV-5) Infections – Pipeline Review, H1 2012
Arthritis – Pipeline Review, H1 2012
Ischemia – Pipeline Review, H1 2012
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2012
Muscle Wasting Disorders – Pipeline Review, H1 2012
AIDS - Related Kaposi's Sarcoma – Pipeline Review, H1 2012

neuroblastoma     pipeline     Revie